Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
The USFDA has issued 5 observations pursuant to the completion of audit
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Subscribe To Our Newsletter & Stay Updated